In light of Friday's announcement that Alnylam was reducing its work force we inquired about the effect this would have on their ongoing development of a potential therapy for HD in collaboration with Medtronic and CHDI and received the following response.

 

“Alnylam, in collaboration with Medtronic and CHDI, remains committed to advancing our novel therapy towards the clinic for the treatment of Huntington’s disease,” said Barry Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals. “We believe our pre-clinical data provide a strong rationale for continued advancement of this program, and we are encouraged by the potential that ALN-HTT may offer to Huntington’s patients.”